Loading...
Market
What will Kisunla™'s market share be in the UK by end of 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market analysis reports from reputable firms like IQVIA or Statista
Story
Eli Lilly's Second 'Game-Changing' Alzheimer's Drug Kisunla™ Approved in UK
Oct 23, 2024, 09:30 AM
Eli Lilly's Alzheimer's treatment, Kisunla™ (donanemab-azbt), has received marketing authorization in Great Britain. The approval by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) allows the drug to be used for treating mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients who are Apolipoprotein E Ε4 heterozygotes or non-carriers. This marks a significant development in Alzheimer's treatment options available in the UK. The drug, which trades under the ticker $LLY, is considered the second 'game-changing' Alzheimer's drug to receive approval in the UK.
View original story
Similar markets
Less than $100 million • 25%
$100 million - $299 million • 25%
$300 million - $499 million • 25%
$500 million or more • 25%
Below $100 million • 33%
$100-$200 million • 33%
Above $200 million • 33%
Below 10% • 33%
10-20% • 33%
Above 20% • 33%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Kisunla > 50% • 25%
Kisunla 30-50% • 25%
Kisunla 10-30% • 25%
Kisunla < 10% • 25%
Less than 20 • 33%
20-40 • 33%
More than 40 • 33%
High uptake (over 10,000 patients) • 25%
Moderate uptake (5,000-10,000 patients) • 25%
Low uptake (1,000-5,000 patients) • 25%
Very low uptake (under 1,000 patients) • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31%+ • 25%